{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"NF155: John Mills, Ph.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/7867efdf\"></iframe>","width":"100%","height":180,"duration":1095,"description":"John Mills, Ph.D., discusses Mayo Clinic Laboratories’ new test to detect neurofascin 155 (NF155) IgG4 antibodies — biomarkers for a rare but serious autoimmune neurological disorder known as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The live cell assay is the first commercially available clinical test of its kind in the U.S. and enables heightened specificity by using flow cytometry to measure NF155 antibodies. Positive findings support clinical and electrophysiological diagnosis of NF155-mediated CIDP and can direct clinicians to more aggressive treatment for the progressive disease. ","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}